Market Overview - U.S. stocks showed mixed performance with the Dow Jones index increasing by 0.64% to 47,673.48, while the NASDAQ decreased by 0.79% to 23,340.59 and the S&P 500 fell by 0.23% to 6,817.03 [1] - Energy shares experienced a rise of 1.2%, while information technology stocks saw a decline of 0.9% [1] Company Highlights - RealReal Inc (NASDAQ:REAL) shares surged after reporting better-than-expected third-quarter financial results and providing fourth-quarter sales guidance above estimates, along with an increase in FY25 sales guidance [2] - enGene Holdings Inc (NASDAQ:ENGN) shares increased by 72% to $10.34 following positive Phase 2 LEGEND study data showing a 63% complete response rate [9] - Energy Vault Holdings Inc (NYSE:NRGV) shares rose by 30% to $4.62 after releasing third-quarter results [9] - Surmodics Inc (NASDAQ:SRDX) shares gained 49% to $40.80 after a court denied the FTC's attempt to block GTCR's acquisition [9] - Vor Biopharma Inc (NASDAQ:VOR) shares dropped by 50% to $9.32 due to the announcement of a $100 million public offering [9] - Salarius Pharmaceuticals Inc (NASDAQ:SLRX) shares fell by 50% to $1.00 after announcing a $7 million underwritten public offering [9] - Outset Medical Inc (NASDAQ:OM) shares decreased by 50% to $6.07 after reporting worse-than-expected third-quarter results and lowering FY25 sales guidance [9] Commodity Market - Oil prices increased by 1.5% to $61.00, while gold rose by 0.3% to $4,134.70 [5] - Silver prices went up by 0.8% to $50.730, whereas copper fell by 0.4% to $5.0845 [5] European Market - European shares showed positive movement with the eurozone's STOXX 600 rising by 1.05%, Spain's IBEX 35 Index gaining 1.05%, and London's FTSE 100 increasing by 0.94% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 down by 0.14%, Hong Kong's Hang Seng up by 0.18%, China's Shanghai Composite down by 0.39%, and India's BSE Sensex rising by 0.40% [7]

Market Overview - U.S. stocks showed mixed performance with the Dow Jones index increasing by 0.64% to 47,673.48, while the NASDAQ decreased by 0.79% to 23,340.59 and the S&P 500 fell by 0.23% to 6,817.03 [1] - Energy shares experienced a rise of 1.2%, while information technology stocks saw a decline of 0.9% [1] Company Performance - RealReal Inc (NASDAQ:REAL) shares surged after reporting better-than-expected third-quarter results and providing fourth-quarter sales guidance above estimates, along with an increase in FY25 sales guidance [2] - enGene Holdings Inc (NASDAQ:ENGN) shares increased by 72% to $10.34 following positive Phase 2 LEGEND study data showing a 63% complete response rate [9] - Energy Vault Holdings Inc (NYSE:NRGV) shares rose by 30% to $4.62 after releasing third-quarter results [9] - Surmodics Inc (NASDAQ:SRDX) shares gained 49% to $40.80 after a court denied the FTC's attempt to block GTCR's acquisition [9] - Vor Biopharma Inc (NASDAQ:VOR) shares dropped by 50% to $9.32 due to the announcement of a $100 million public offering [9] - Salarius Pharmaceuticals Inc (NASDAQ:SLRX) shares fell by 50% to $1.00 after announcing a $7 million underwritten public offering [9] - Outset Medical Inc (NASDAQ:OM) shares decreased by 50% to $6.07 following worse-than-expected third-quarter results and a cut in FY25 sales guidance [9] Commodity Market - Oil prices increased by 1.5% to $61.00, while gold rose by 0.3% to $4,134.70 [5] - Silver traded up by 0.8% to $50.730, whereas copper fell by 0.4% to $5.0845 [5] European Market - European shares showed positive movement with the eurozone's STOXX 600 rising by 1.05%, Spain's IBEX 35 Index gaining 1.05%, and London's FTSE 100 increasing by 0.94% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 down by 0.14%, Hong Kong's Hang Seng up by 0.18%, China's Shanghai Composite down by 0.39%, and India's BSE Sensex up by 0.40% [7]

Market Overview - U.S. stocks exhibited mixed trading, with the Nasdaq Composite declining over 0.4% on Tuesday. The Dow increased by 0.13% to 47,430.01, while the S&P 500 fell by 0.15% to 6,823.18 [1] - Energy shares rose by 0.9%, whereas information technology stocks decreased by 0.7% [1] Company Performance - Sea Ltd (NYSE:SE) saw its shares rise approximately 4% after reporting fiscal Q3 2025 results, with revenue increasing by 38.3% year-on-year to $5.99 billion, surpassing analyst expectations of $5.65 billion. However, earnings per share were 59 cents, missing the consensus forecast of 77 cents [2] Commodity Market - In commodity trading, oil prices increased by 1.1% to $60.76, gold rose by 0.7% to $4,151.60, silver gained 1.4% to $51.030, while copper fell by 0.3% to $5.0915 [5] European Market - European shares experienced gains, with the eurozone's STOXX 600 rising by 0.8%, Spain's IBEX 35 Index up by 0.8%, London's FTSE 100 increasing by 0.8%, Germany's DAX 40 gaining 0.2%, and France's CAC 40 climbing by 0.9% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 down by 0.14%, Hong Kong's Hang Seng up by 0.18%, China's Shanghai Composite declining by 0.39%, and India's BSE Sensex rising by 0.40% [7] Notable Stock Movements - MSP Recovery Inc (NASDAQ:MSPR) shares surged 104% to $0.65 after a previous decline of 15%. Quoin Pharmaceuticals Ltd (NASDAQ:QNRX) shares increased by 51% to $12.47 following the announcement of achieving target loadings for proprietary delivery technologies. Surmodics Inc (NASDAQ:SRDX) shares rose by 50% to $41.08 after a court denied the FTC's bid to block an acquisition [9] - Conversely, Vor Biopharma Inc (NASDAQ:VOR) shares dropped 48% to $9.87 due to a public offering announcement, while Salarius Pharmaceuticals Inc (NASDAQ:SLRX) fell 50% to $1.00 after announcing a $7 million public offering. Outset Medical Inc (NASDAQ:OM) shares decreased by 42% to $7.04 following worse-than-expected Q3 results and a lowered FY25 sales guidance [9]

Core Viewpoint - Salarius Pharmaceuticals, Inc. has announced a public offering expected to raise approximately $7 million before expenses, which will be used to advance clinical development and for general corporate purposes [1][5]. Offering Details - The offering consists of 2,514,335 shares of common stock and pre-funded warrants for 2,152,331 shares, along with Series A and Series B Warrants for a total of 4,666,666 shares each [2]. - The public offering price is set at $1.50 per share and accompanying warrants, and $1.4999 per pre-funded warrant and accompanying warrants [2]. - Ladenburg Thalmann & Co. Inc. is the sole book-running manager for the offering [3]. Closing Conditions - The closing of the offering is anticipated on or about November 12, 2025, contingent upon the completion of a proposed business combination with Decoy Therapeutics Inc. [4]. - An option has been granted to the underwriter to purchase an additional 699,999 shares and/or warrants within 45 days at the public offering prices [4]. Use of Proceeds - The net proceeds from the offering will be allocated to advancing clinical development programs, paying off Decoy's promissory notes, and for general corporate purposes including working capital and capital expenditures [5]. Warrant Details - Pre-funded warrants have an exercise price of $0.0001 and are immediately exercisable, while Series A and Series B Warrants have an exercise price of $1.50, with different exercise periods [6]. Company Background - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, with its lead candidate seclidemstat currently in a Phase 1/2 clinical study [10]. - Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company utilizing machine learning and AI for drug development, focusing on respiratory viruses and GI cancers [11].

As filed with the Securities and Exchange Commission on October 21, 2025 Registration No. 333-284368 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 7 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 2450 Holcombe Blvd. Suite X Houston, TX 77021 713 ...

Core Points - Salarius Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement, as of October 10, 2025, following its earlier compliance with Listing Rule 5550(a)(2) on September 9, 2025 [1][2] Group 1: Compliance and Merger - The company is now fully compliant with all Nasdaq listing requirements, which is a significant step towards its planned merger with Decoy Therapeutics [2] - Salarius entered into a definitive merger agreement with Decoy Therapeutics on January 13, 2025, where Decoy will merge with a wholly owned subsidiary of Salarius, forming a new entity named Decoy Therapeutics [3] - Following the compliance notice, Salarius will be under a Mandatory Panel Monitor for one year, during which any non-compliance could lead to a delisting determination [4] Group 2: Merger Details and Pipeline - The merger is expected to create multiple value-creating opportunities through Decoy's pipeline of peptide conjugate therapeutics, which targets unmet medical needs in respiratory infectious diseases and GI oncology [5] - The combined company will focus on advancing Decoy's lead asset, a pan-coronavirus antiviral, and other programs targeting flu, COVID-19, RSV, and GI cancers [7] - Salarius' existing drug candidate, SP-3164, will be integrated into the new company's drug development strategy [5][6] Group 3: Company Backgrounds - Decoy Therapeutics is a preclinical-stage biotechnology company utilizing machine learning and AI for rapid design and manufacturing of peptide conjugate drug candidates [9] - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company with two drug candidates focused on cancer treatment, including seclidemstat and SP-3164 [10][11]

Core Points - Salarius Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement, as of October 10, 2025, following prior compliance with Listing Rule 5550(a)(2) on September 9, 2025 [1][2] - The company is in the process of a planned merger with Decoy Therapeutics, which is expected to create multiple value-creating opportunities through Decoy's peptide conjugate therapeutics pipeline [3][5] - The combined company will be led by Decoy's co-founders and Salarius' acting CEO, indicating a strong leadership structure for the new entity [6] Compliance and Monitoring - Salarius is now fully compliant with all Nasdaq listing requirements, which is crucial for the merger with Decoy Therapeutics [2] - The company will be under a Mandatory Panel Monitor for one year starting October 10, 2025, to ensure ongoing compliance with the Equity Standard Requirement [4] Merger Details - The merger agreement with Decoy Therapeutics involves a business combination where Decoy will merge with a wholly owned subsidiary of Salarius, forming a new entity named Decoy Therapeutics [3] - Decoy's pipeline focuses on unmet medical needs in respiratory infectious diseases and GI oncology, with plans to advance a pan-coronavirus antiviral and other programs within the next 12 months [7] Product Development - The combined company aims to enhance Decoy's IMP3ACT platform for rapid design and manufacturing of peptide conjugate therapeutics, while also incorporating Salarius' SP-3164 into a targeted drug candidate [5] - Salarius' lead candidate, seclidemstat, is being studied for hematologic cancers, with ongoing clinical trials at MD Anderson Cancer Center [8][11]

As filed with the Securities and Exchange Commission on September 23, 2025 Registration No. 333-284368 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 2450 Holcombe Blvd. Suite X Houston, TX 77021 7 ...

Search fieldEntering text into the input field will update the search result belowEntering text into the input field will update the search result below ...

HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement. By meeting the Minimum Bid Price Requirement, Salarius has achieved one of the milestones in regaining compliance with all Nasdaq continued listing standards. As previously disclosed on A ...